Merus NV (MRUS.OQ)
19 Apr 2018
Tue, Mar 20 2018
* MERUS AND VALL D'HEBRON INSTITUTE OF ONCOLOGY ANNOUNCE RESEARCH COLLABORATION TO DEVELOP INNOVATIVE BISPECIFIC ANTIBODIES FOR THERAPEUTIC APPLICATIONS IN TREATMENT OF CANCER Source text for Eikon: Further company coverage:
* MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES
* MERUS ANNOUNCES $55.8 MILLION PRIVATE PLACEMENT OFFERING OF COMMON STOCK
Jan 8 Simcere Pharmaceutical Group :
* MERUS PROVIDES CLINICAL UPDATES FOR MCLA-117 AND MCLA-158 PROGRAMS
A federal appeals court on Tuesday refused to reconsider its ruling that a patent Regeneron Pharmaceuticals Inc asserted against rival Merus NV is unenforceable because it was obtained through deception.
* MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS
- ROTY Volume 1 Edition 83: Thank You For Your Patience - Launch Day Has Arrived!
- ROTY Edition 1 Volume 82: Launch Preview And Adding To A Position
- ROTY Edition 1 Volume 81: We Have A Launch Date!
- ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk
- Merus: This ROTY Holding Flashed A Buy Signal
- Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration